|
|
|
|
| LEADER |
01594nam a2200265 u 4500 |
| 001 |
EB001892130 |
| 003 |
EBX01000000000000001055277 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
200301 r ||| eng |
| 100 |
1 |
|
|a Chao, Yi-Sheng
|
| 245 |
0 |
0 |
|a HPV testing for primary cervical cancer screening
|h Elektronische Ressource
|b a health technology assessment
|c Yi-Sheng Chao [and 16 others]
|
| 260 |
|
|
|a Ottawa (ON)
|b Canadian Agency for Drugs and Technologies in Health
|c 2019, 2019 Mar
|
| 300 |
|
|
|a 1 online resource
|b illustrations
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 653 |
|
|
|a Uterine Cervical Neoplasms / diagnosis
|
| 653 |
|
|
|a Diagnostic Screening Programs
|
| 653 |
|
|
|a Human Papillomavirus DNA Tests
|
| 710 |
2 |
|
|a Canadian Agency for Drugs and Technologies in Health
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a CADTH optimal use report
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK543088
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
| 082 |
0 |
|
|a 140
|
| 520 |
|
|
|a The objective of this health technology assessment (HTA) is to address the policy question by assessing the diagnostic test accuracy, clinical utility, safety, cost-effectiveness, patients' experiences and perspectives, ethical issues, and implementation issues of HPV testing as a primary screening tool for cervical cancer screening. This HTA was conducted to inform decision-making, policy development, capacity planning, and recommendations around primary HPV-based testing for cervical cancer screening
|